Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

ReviewCardiovascular diabetology. Endocrinology reports· Jul 2026

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Reza Khademi, Saeed Shoar

Read paper

EndocrinologyReviewTreatmentQ1IF 14.6

SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death rates.

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Reza Khademi, Saeed Shoar

Cardiovascular diabetology · Jul 2026 · Q1 in Internal Medicine

Background

Heart failure (heart failure) is a major cardiovascular complication of type 2 diabetes mellitus (T2DM).

Methods

Emerging data from meta-analyses, subgroup analyses, and observational studies suggest possible additive benefits of combination therapy; however, most evidence is indirect and not derived from dedicated randomized heart failure trials.

Results

30-37%

SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths

More results

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both improve cardiovascular outcomes, but their comparative roles in heart failure and the potential value of combination therapy remain uncertain.

More results

In contrast, GLP-1 receptor agonists have a more modest effect on heart failure hospitalization (approximately 11% risk reduction; HR 0.89) while primarily reducing atherosclerotic cardiovascular events and supporting weight and metabolic control.

“

Conclusion · 1 of 2

SGLT2 inhibitors are established therapies for reducing heart failure outcomes, whereas GLP-1 receptor agonists primarily address cardiometabolic risk with uncertain direct heart failure benefit.

Conclusion · 2 of 2

Combination therapy is mechanistically plausible but remains insufficiently supported by dedicated randomized evidence in heart failure populations. Further prospective trials are required to define its clinical role.

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Related papers